ABSTRACT
(B6xA)F1 hybrid hematopoietic cells [(B6xA)/B6 chimeras] reject A strain (Skn-incompatible) skin grafts. Our studies were designed primarily to test the inference that (B6XA)FI lymphoid cells, after differentiating in B6 recipients, which lack the Skn alloantigens of A strain mice, may make an Skn-related, skin-selective autoimmune response when returned to their native (B6xA)FI habitat. Severe cutaneous lesions did, indeed, ensue after spleen cells of (B6xA)/B6 chimeras were transferred to (B6XA)FI recipients, provided that three conditions were met-namely, (i) priming of the (B6xA)/B6 chimeric donor by grafting and rejection of Sknincompatible A strain skin grafts, (ii) stimulation of the recipient's skin as from shaving, at which sites the lesions were mainly located, and (iii) pretreatment of the (B6xA)FI recipients with cyclophosphamide or sublethal irradiation. Spleen cells of control female chimeras primed by grafting and rejection of H-Y (Skn-compatible) B6 male skin failed to incite the Skn-typical cutaneous lesions in (B6XA)FI recipients, indicating that these lesions were Skn-specific and not a nonspecific consequence of incompatible skin grafting per se. Normally compatible A strain skin grafts, but not Skn-compatible B6 skin grafts, were rejected by cyclophosphamide-treated (B6xA)FI recipients of (B6xA)/B6 spleen cells from Skn-primed chimera donors. Treatment of primed chimeras' spleen cells with antiserum to H-23 (A strain) specifically abolished their capacity to adoptively incite the Skn-related autoimmune syndrome, confirming that the immune cells responsible are of (B6xA)F1 origin and are not residual B6 derivatives. These findings add weight to the status of Skn systems as agents of tissue-selective histoincompatibility and, perhaps, of clinical disorders with a known or suspected autoimmune basis affecting the skin.
Graft-versus-host disease (GVHD) results when immunocompetent cells are transferred into an immunocompromised genetically different individual. Skin is often a prime affected organ, and histologic alterations in skin biopsies have often been used as criteria for the diagnosis of GVHD (1, 2) .
Cutaneous manifestations like GVHD have also been described in humans after autologous or syngeneic bonemarrow transplantation (3, 4) and after discontinuance of cyclosporin A treatment succeeding syngeneic bone-marrow transplantation in rats (5, 6 ) and mice (7, 8) . Because in these instances no histoincompatibility was evident, the syndrome has been termed syngeneic GVHD (5) and may, in fact, represent an autoimmune disease, as suggested by Fischer et al. (9) .
Although the mechanism is unclear, syngeneic GVHD in the rat appears to involve both CD4+ and CD8+ T lymphocytes (10) and possibly results from the presence of autoreactive T cells in the absence of an intact autoregulatory system (11) . Indeed, examination of T-lymphocyte maturation during cyclosporine treatment after syngeneic bonemarrow transplantation revealed the emergence of autoreactive T cells in the rat (12) but, within the limits tested, not in the mouse (13) .
Using the rat model of syngeneic GVHD, Hess et al. (14) reported that the response was directed against self-class II major histocompatibility complex antigens. Antigenic targets of syngeneic GVHD might also include tissue-specific minor histocompatibility antigens. Indeed, acute skin GVHD directed against minor histocompatibility antigens has been reported in major histocompatibility complex-matched murine models (15, 16) .
Boyse et al. (17) described a mouse model in which lethally irradiated C57BL/6 (B6) mice restored with (C57BL/6 x A/J)F1 (B6XA)F1 spleen cells, designated (B6xA)/B6 chimeras, reject A/J (A) or (B6xA)F1 skin grafts, despite remaining hematopoietic chimeras. This immunologic reaction arises from differences between B6 and A strains in their Skn alloantigens (18) . The Skn alloantigens are encoded by two unlinked genes designated Skn-J and Skn-2 (19) . Immunohistochemical labeling of skin tissue (20) Chimeras were immunized against Skn-1.1 and Skn-2.1 alloantigens by skin grafting with A strain tail skin (21) no sooner than 8 weeks after irradiation.
Pretreatment of (B6xA)F1 Recipients Before Receipt of Spleen Cells from Chimeras. Recipients were 4-8 months old. Skin of the dorsal thorax was shaved 1 day before cell receipt of spleen cells from chimeras. Where indicated, pretreatments also included skin grafting and/or immunosuppression as follows.
Grafting. One day before cell transfer, A and/or B6 tail skin was applied to the dorsal thorax and sutured. Grafts were observed daily for signs of rejection for 90 days and were scored as rejected when only a scab remained at the graft site.
Immunosuppression. Four hours before cell transfer, recipients received cyclophosphamide (Cytoxan; CTX) (Mead Johnson) or whole-body irradiation delivered from the 137Cs irradiator, as noted in text.
Cell Transfer. Dispersed spleen cells from (B6xA)/B6 chimeras that had rejected one or more A strain skin grafts (hereafter denoted Skn-immune cells) were prepared in phosphate-buffered saline. All recipients were examined daily for epidermal changes. At various days after cell transfer, skin biopsies were examined histologically after staining with hematoxylin/eosin.
Serological Identification of Skn-Immune Cells. Sknimmune cells were prepared as above. Cells (100 x 106) were treated with 48 ,ul of undiluted H-2a or H-2b antiserum. Phosphate-buffered saline was added to a final volume that would deliver the appropriate number of cells to the recipient i.v. in 0.2-ml inoculum. Where noted, selected rabbit serum as a source of complement was also added at 120 per 100 x 106 cells; cells, antiserum, and complement were mixed and incubated for 30 min at 37°C before i.v. injection. The concentration of H-2 antisera used was determined by flow cytometric titration and represents >99% staining of (B6xA)F1 spleen cells. Antiserum against the serologically determined male-specific antigen was obtained from B6 female mice that had rejected B6 male skin grafts and served as a negative control.
RESULTS
Transient Microscopic Lesions in Shaved Skin of Normal (B6xA)F1 Mice Receiving Skn-Immune Cells from (B6xA)/B6 Chimeras. Spleen cells from chimeras that had rejected A strain skin grafts (denoted "Skn-immune cells") were transferred i.v. to normal (B6xA)F1 recipients from which skin had previously been shaved in the thoracic area. No gross changes were seen (Table 1 , group A), but microscopic lesions were evident at 3-7 days and had resolved by about day 10.
These microscopic lesions were mainly confined to the shaved areas and comprised epidermal-dermal splits, dermal infiltrate, epidermal dyskeratosis, and spongiosis (Fig. 1 ). Acanthosis appears due, in part, to shaving because mild acanthosis was seen also in the shaved area of control (B6xA)F1 recipients that had received spleen cells from normal (B6xA)F1 donors and that, with minor exceptions, exhibited none of the other changes noted.
In accord with serological data on the location of Skn antigens, obtained with Skn antisera and monoclonal antibodies (20) , the lesions appeared to affect the keratinocytic epidermis as a whole, rather than affecting any particular layer.
More Severe Cutaneous Lesions in Recipients Treated with CTX or Whole-Body Irradiation. Because the lesions in normal (B6XA)F1 recipients of Skn-immune cells from (B6xA)/B6 chimeras were so mild, in contrast to the chimeric donors' vigorous rejection of A strain skin, ostensibly by the same immunocompetent (B6xA)F1 cell population of the chimeras before adoptive transfer, we resorted to the use of immunosuppressive agents, which in comparable circumstances allow more effective transfer of adoptive immune responses (24, 25) .
Consequently, the study detailed above was repeated with the added factor that the (B6XA)F1 recipients were treated with CTX or whole-body irradiation 4 hr before receiving Skn-immune cells. Under these conditions, gross visible lesions ensued (ranging from epidermal scaling to crusts overlying epidermal erosion or ulceration) were again confined to shaved skin, and in this case persisted throughout the observation periods up to 3 weeks in all 8 recipients given CTX ( that resolved shortly after the 3-week observation period to others persisting as long as 10 weeks, at which time the mice were euthanized. In accord with the implication of Skn-specific adoptive immunization, only one of five CTX-treated recipients of spleen cells from chimeras not primed by grafting and rejection of A strain skin exhibited visible lesions ( CTX or irradiation was, in some instances, accompanied by parakeratosis, microabscesses in the stratum corneum, and exaggerated acanthosis.
Extensive histologic examination revealed no pathological changes in organs other than skin (lung, liver, kidney, heart, stomach, thyroid, trachea, small intestine, pancreas, and uterus), aside from mild lymphoid hyperplasia and more pronounced splenic hematopoiesis attributable to recovery from CTX/irradiation treatment and ongoing immune reactivity. These negative findings do not necessarily imply skin-specific autoimmunity because the contributory factor of nonspecific cutaneous stimulation, as in shaving, that appears a prime factor in the occurrence and location of skin lesions, as noted above, was absent in tissues other than skin.
Skn Specificity of Cutaneous Lesions. The studies above reveal that severe skin lesions in (B6xA)F1 recipients of Skn-immune spleen cells depend on three factors-namely, (i) priming of (B6xA)/B6 chimeric donors with Sknincompatible A strain skin grafts that are rejected, (ii) pretreatment of recipients with CTX or irradiation, and (iii) disturbance of skin, represented by shaving.
With respect to the first of these factors, priming of the chimeric donor, whether the recipient's lesions truly represent a specific anti-Skn response or a nonspecific response that might be activated by skin grafting and rejection per se needs to be answered. This question was addressed by two studies. CTX-treated or irradiated (B6XA)F1 recipients, shaved as usual, were given spleen cells from unprimed syngeneic (B6XA)Fl donors. Neither gross nor microscopic cutaneous lesions were seen ( Table 1 , groups E and F).
In a second study, the three factors necessary for severe cutaneous lesions were reproduced with the variation that the donor (B6XA)/B6 chimeras (female) were primed by grafting and rejection of B6 male skin grafts, thereby eliminating Skn and all other histoincompatibilities other than H-Y malespecific antigen disparity. Again, neither gross nor microscopic lesions were seen in female CTX-treated shaved (B6xA)F1 recipients ( That skin-targeted autoimmunity occurs when these conditions are met implies autoregulation with respect to selfSkn antigens in normal mice.
In other systems, immunoregulation, to both self-and foreign antigens, evidently involves lymphocyte subsets that are susceptible to immunosuppressive agents. North and colleagues observed that CTX (24) or sublethal irradiation (26) facilitates rejection of tumor transplants if applied at a critical time when tumor-specific Lyt-2+ cells prevail but before the subsequent rise in host Lyt-1+ suppressor cells supervenes (26) . In this model system with a variety of tumors and mouse strains, the Lyt-1+ immunoregulatory suppressor cells were further identified as L3T4+ (CD4+) cells (27, 28) . In the BALB/c strain of mice, protection against Leishmania major was also found to depend on deletion of CD4+ suppressor cells (29) .
Similar findings have been reported in experimental models of autoimmunity. In the rat, adoptive transfer of synge- neic GVHD required that recipients be treated with high-dose irradiation or CTX (9) , and cotransfer of combined W3/25+ (CD4+), and OX8+ (CD81) T cells from normal donors restrained the adoptive transfer (30) . Likewise, nonobese diabetes of mice (NOD) was transferable with spleen cells from diabetic donors only when the young nondiabetic recipients were irradiated (25, 31) , and resistance was conferred by providing a radiosensitive CD4+ cell (31) . No comparable definition of lymphocyte subsets involved in Skn-based cutaneous autoimmunity and autoregulation has yet, to our knowledge, been undertaken.
Participation of tissue-resident cells in immunoregulation cannot be discounted. In an in vitro model of experimental autoimmune uveoretinitis, retinal glial cells could suppress organ-specific anti-self T-helper lymphocytes (32) . In murine skin, Thy-1+ dendritic epidermal T cells, expressing yv antigen receptors, have a suggested role in immune surveillance by recognizing damaged self-antigens (33) . Indeed, isolated dendritic epidermal T cells can respond to selfantigen on cultured keratinocytes (34) , but whether the ultimate response is a protective or aggressive mechanism is uncertain. A function for dendritic epidermal T cells in protection against autoimmunity, however, is indirectly supported by the correlation of increased numbers of Thy-1+ cells observed in a site-restricted manner after recovery from autoreactive cutaneous GVHD in mice and by subsequent resistance to epidermal attack (35) .
In regard to clinical relevance, there can be little doubt that the Skn genes expressed by keratinocytes, like the CDencoding genes expressed by lymphocytes, have their counterparts in humans and may be similarly involved as targets of GVHD and autoimmunity affecting the skin. Particular attention is drawn to human skin disorders of known or suspected autoimmune origin, in which damage to the skin replicates or initiates local lesions (the Koebner response) because that is a prime factor in Skn-based cutaneous autoimmune skin lesions in the mouse. The Koebner response has been seen in connection with psoriasis and several other dermatoses; to the extent that Skn cutaneous autoimmunity may properly be regarded as a relative of the Koebner response, findings such as those reported here with the Skn system may have a bearing on these human disorders.
